tbuckley/cabot-search huggingface dataset:
A multicenter, phase III study of carboplatin/paclitaxel versus oral uracil-tegafur as the adjuvant chemotherapy in resected non-small cell lung cancer (NSCLC): Planned interim analyses
Authors: S. Toyooka, K. Hotta, H. Nakamura, M. Nakata, H. Tada, M. Yamashita, N. Watanabe, J. Sakamoto, M. Aoe, H. Date
Journal: Journal of Clinical Oncology (2009)

7560 Background: Recent studies have demonstrated that adjuvant chemotherapy provides a survival benefit in patients with resected NSCLC. In Japan, uracil-tegafur has been recognized as a standard adjuvant strategy for resected NSCLC, however, carboplatin based adjuvant chemotherapy has not been fully evaluated for the treatment of NSCLC patients in an adjuvant setting. The present phase III study assessed the efficacy and safety of carboplatin/paclitaxel and oral uracil-tegafur as the first study to compare intravenous and oral drugs in resected stage IB-IIIA NSCLC. Methods: The patients with pathological stage IB-IIIA NSCLC who underwent complete resection were randomized 1:1 to carboplatin (AUC 5) /paclitaxel (175 mg/m 2 ) every 3 week for 4 cycles (A arm) or uracil-tegafur (250 mg/m 2 ) daily for 2 years (B arm). The primary endpoint was overall survival (OS) and secondary endpoints were disease-free survival and toxicity. The accrual of 200 patients per arm is required to demonstrate an improvement of OS (15% increase) in the A arm compared to B arm. Randomization was stratified by histology and tumor stage. An interim analysis was planned to perform on the first 200 patients recruited and data of survival and toxicity were examined in the first 100 patients. Results: Between November 2004 and November 2008, 200 patients from 31 Japanese centers were randomized and the first 100 patients were included for interim analysis. Median age was 69 (range; 50–80) years. Ninety-eight patients had PS of 0–1 and 2 patients had PS of 2. Sixty-seven patients were male and 23 patients were female. Sixty patients had adenocarcinoma, 30 had squamous cell carcinoma, and 10 had other histologies. Disease stage was IB in 53, IIA in 14, IIB in 19, and IIIA in 14 patients. Toxicities observed during adjuvant chemotherapy were well tolerable. There was no toxic death. The median survival time of A and B arms combined was 4.1 year. Monitoring Committees approved to continue the present study. Conclusions: The present phase III trial with carboplatin/paclitaxel or uracil-tegafur is feasible with manageable toxicity. The study is on course to achieve its primary endpoint. [Table: see text]
The 70-gene profile and chemotherapy benefit in 1,600 breast cancer patients
Authors: R. A. Bender, M. Knauer, E. J. Rutgers, A. M. Glas, F. A. de Snoo, S. C. Linn, L. J. Van 't Veer
Journal: Journal of Clinical Oncology (2009)

512 Background: The 70-gene expression profile (MammaPrint) is validated as an independent prognostic indicator for breast cancer patients with T1–2 node-negative and positive disease regardless of estrogen receptor status. Here we present the relationship between MammaPrint outcome and chemotherapy benefit in the adjuvant setting. Methods: We performed a pooled analysis of 1,637 patients with MammaPrint outcomes (T1–2, node-negative and positive invasive breast cancer and median FU 7.1 yrs) to determine the chemotherapy benefit of patients treated with adjuvant chemotherapy in addition to endocrine therapy. Patients were collected from 7 large datasets at multiple institutions across Europe. Results: In this meta-analysis, MammaPrint assigned 772 patients (47%) to “low risk” and 865 (53%) to “high risk”. In total 349 patients were treated with endocrine therapy alone, whereas 226 were treated with both chemo- and endocrine therapy. Patients with poor prognosis MammaPrint profile had a substantial benefit from chemotherapy: At 5 years, distant disease-free survival was improved from 69% to 88% (HR 0.28 (95% CI 0.14–0.56, p&lt;0.001) when chemotherapy was added to hormonal therapy. The results remained significant in multivariate analysis including stratification by standard clinico-pathologic prognostic factors. Patients classified by MammaPrint as good prognosis (“low risk”) had no significant benefit from chemotherapy (p=0.962). Conclusions: The 70-gene MammaPrint profile is not only a strong and independent prognostic indicator for patients with early stage breast cancer, but it may also be predictive for the benefit of chemotherapy. While MammaPrint “high risk” classified patients demonstrate a clear benefit from adjuvant chemotherapy added to hormonal therapy, patients classified by MammaPrint as “low risk” for recurrence do not appear to benefit from the addition of chemotherapy to hormonal treatment alone. [Table: see text]
Irinotecan (CPT-11) combined with UFT as first line treatment of advanced colorectal carcinoma-A phase II study
Authors: Y. Cohen, K. Shulman, E. Idelevich, M. Ben-Shachar, J. Honnigman, H. Haiat, J. Zidan, A. Hubert, A. Kuten, A. Beny
Journal: Journal of Clinical Oncology (2004)

3742 Background: The combination of 5-FU+LV with irinotecan as first line treatment of advanced colorectal cancer (ACRC) has shown higher antitumor activity similar to 5-FU+LV with the same progression free survival. The aim of this study is to determine the side-effect profile, dose limiting toxicity and response rate, on an outpatient basis.We present the preliminary data of the combination of UFT and CPT-11 as first line treatment of ACRC. Methods: Inclusion criteria: age >18, ECOG <2, measurable disease, no previous treatment for advanced disease (adjuvant chemotherapy more then 6 months), signed informed consent and adequate hepatic, renal and hematological function. Exclusion criteria: Serious concurrent medical disorders, prior malignancy, pregnancy or breast-feeding and patients with poor compliance. UFT (250mg/M2 orally) was given twice daily for 21 days followed by 7 days rest and Irinotecan (160mg/M2) was given every 14 days. 64 patients were included. 45 patients were assessable for response and 64 for toxicity. 278 (1–12) cycles were administrated. Median No. Of cycles were 4. Median age: 67(32–82), gender (M/F) 32/32, location (colon/rectum) 39/15, Metastatic sites: liver 30(46%), lung 7(11%), liver+lung 9 (14%), abdominal 13 (20%), other 5 (8%). Median CEA level 295 ng/ml (range: 0,2 - 3953). Toxicity summary grade 3–4: Neutropenia 10 (15%), Diarrhea 18 (28%), Asthenia 6 (9%), Vomiting 9 (14%), Stomatitis2 (3%), neutropenic fever 6 (9%), blood transfusion- 9 (14%). Results: Complete reasponse - 4 (9%), Partial response - 11 (24%), Stable disease - 9 (20%) and Tumor progression - 21 (47%). Median time to progression was 92 days (30–365). Conclusions: This regimen appears feasible with acceptable toxicity except for grade III diarrhea, on an outpatient treatment basis, with significant antitumor activity, similar to that seen with other fluoropyrimidine-based combination regimens but without the requirement for indwelling catheters. No significant financial relationships to disclose.
Randomized phase II/III clinical trial of induction chemotherapy (ICT) with either cisplatin/5-fluorouracil (PF) or docetaxel/cisplatin/5-fluorouracil (TPF) followed by chemoradiotherapy (CRT) vs. crt alone for patients (pts) with unresectable locally advanced head and neck cancer (LAHNC)
Authors: R. Hitt, J. Grau, A. Lopez-Pousa, A. Berrocal, C. García-Giron, J. Belon, J. Sastre, J. Martinez-Trufero, H. Cortés-Funes, J. Cruz-Hernandez
Journal: Journal of Clinical Oncology (2006)

5515 Background: we have previously reported that ICT plus CRT is more active than CRT alone in pts with unresectable LAHNC (Hitt et al: ASCO 2005, abstract 5578). Here we present new data of efficacy and time to progression (TTP) in this trial. Methods: Patients: eligible pts included those with unresectable LAHNC, measurable disease, adequate organ function and ECOG 0–1. Pts were stratified according to primary tumor site. Treatment: Induction chemotherapy regimens (3 cycles): PF : P 100 mg/m 2 day (d) 1, then F 1000 mg/m 2 c.i. d1–5 q 21d; TPF: T 75 mg/m 2 d1, P 75 mg/m 2 d1, F 750 mg/m 2 c.i. d 1–5 q 21 d plus G-CSF and ciprofloxacin. Chemoradiotherapy: conventional RT up to 70 Gy plus P 100 mg/m 2 d 1–22–43 Results: Patients: a total of 310 pts have been accrued. Pts/tumor characteristics (ECOG, age, primary site, T/N stage) were well balanced among the three arms. T/N stage: T3–4 (88%); N2–3 (63%); pharynx-oropharynx site (62%). Treatment: Median number of cycles of ICT: 3; median dose of RT: 70 Gy, median number of cycles of P during RT in three arms: 3. Efficacy: Complete Response: 70% (ICT + CRT) vs. 49% (CRT alone) (p = 0.01). The response rate was similar between TPF and PF. Time to progression (TTP) in months: 16 (TPF + CRT); 12 (PF + CRT) vs 8 (CRT alone) (log-Rank= 0.02). G 3/4 toxicity (NCI criteria): Febrile neutropenia: 21% (TPF); mucositis: 10% (PF). Mucositis was observed in 55% (TPF + CRT), 60% (PF + CRT) and 36% (CRT alone) of the pts, respectively Conclusions: The results of the present randomised clinical trial demonstrate that the combination of ICT + CRT significantly increases the complete response rate and prolongs TTP when compared to CRT alone in patients with unresectable LAHNC. No significant financial relationships to disclose.
Selenomethionine Se 75 thymus scans in myasthenia gravis
Authors: R. J. Cowan
Journal: JAMA (1971)

Of 20 patients with myasthenia gravis studied with selenomethionine Se 75 mediastinal scans, two (10%) had positive scans. Both of these patients underwent surgery with removal of a thymoma. Since this radiopharmaceutical is accumulated in numerous tissues, false-positive studies may present some difficulty. The adult thymus, in the absence of a thymoma, does not appear to concentrate selenomethionine Se 75 sufficiently for external scanning. Negative studies may therefore be of value in ruling out the presence of a thymoma.
Abstract 12533: Low Endothelial Shear Stress Modulates Coronary Remodeling and Plaque Eccentricity Toward a High-Risk Profile: An in-vivo Computed Tomography Angiography Human Study
Authors: Sotirios Katranas, Anastasios Kelekis, Antonios Antoniadis, Yiannis Chatzizisis, Antonios Ziakas, George Giannoglou
Journal: Circulation (2012)

Background: Plaque eccentricity and remodeling decisively affect the natural history of atherosclerosis. Highly eccentric plaques and expansively remodeled regions are associated with a high-risk p...
The cell transfer immunotherapy of intra-arterial infusion for the patients with liver metastases of gastrointestinal and pancreas cancer
Authors: U. Toh, H. Yamana, T. Fujii, K. Tayama, K. Miwa, H. Horiuchi, M. Kokanemaru, K. Shirouzu
Journal: Journal of Clinical Oncology (2005)

2581 Background: T cells stimulated in the presence of IL-2 and autologous tumor cells (AuTL) may have high potential for efficacy as cellular immunotherapy for the liver metastatic cancer using the intraarterial approach without increasing toxicity. Methods: Ten patients with liver metastases of recurrent gastricintestinal cancer (4 esophageal cancers, 1 gastric cancer, 2 colon cancers, 3 pancreas cancers) were enrolled in a pilot clinical trial. The PBMCs were obtained by leukopheresis and cultured approximate 2 weeks for activation. AuTLs were evaluated for CD markers (CD3, CD4, CD8 etc.) and cytokine production after culture. AuTL were infused though a reservior port system via hepatic artery 2x/month for 2–3 months.Results: Toxicity related to cell transfer therapy at all treatments was minimal. 1 patient had completed response (CR) for 5 months, 3 patients had partial responses (PR) for 12, 6 and 5 months, 2 patient had stable disease (SD) for 6 months and 4 patient had progressive disease (PD). After treatments, two of 6 patients who experienced PR disease had T cell clonality by testing their PBMC using T cell receptor beta chain PCR. In 4/10 and 8/10 patients, CD3+CD8+ T cells and CD56+ NK cells increased after 2-week culture, respectively. Conclusions: This study demonstrate that AuTL can be infused safely through hepatic artery with minimal toxicity. Infusions of AuTLs with high Th1 cytokine might be effective to the patients with refractory liver metastases of recurrent gastricintestinal or pancreas cancer. No significant financial relationships to disclose.
Identification of a predictive gene expression marker for recurrence in childhood ependymoma using microarray analysis
Authors: N. K. Foreman, J. Straessle, M. Handler, A. Donson
Journal: Journal of Clinical Oncology (2005)

1531 Background: Ependymomas (EPN) account for 6–12% of all intracranial tumors in children. Even after complete resection and radiation, almost half the patients are likely to relapse. The role of chemotherapy in this tumor is uncertain. If children, who are at high risk of relapsing, could be identified at diagnosis then innovative therapy could be offered to them. Methods: RNA was extracted from 9 EPN specimens obtained at diagnostic surgery with appropriate consent and IRB approval. Retrospective clinical outcomes were obtained from the neuro-oncology data base with IRB permission. Extracted RNA was applied to Affymetrix HG-U133 plus2 microarray chips. To evaluate the results of microarray analysis, the data mining program GeneSpring was utilized. Results gathered from data mining were validated by quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) and immunohistochemistry. Results: Interleukin-13 Receptor alpha 2 (IL13RA2) mRNA expression was identified as a potential marker of recurrence. Microarray analysis showed a significant (p=0.045, 2-tailed t-test) increase in the expression levels of IL-13RA2 mRNA in those whose EPN subsequently recurred (n=6) versus those who did not recur (n=3). Mean IL13RA2 mRNA expression was over 40 times higher in the recurrent group versus the non-recurrent. qRT-PCR and immunohistochemistry confirmed the over-expression of IL-13RA2 in the recurrent EPN group. Conclusions: Over-expression of IL-13RA2 mRNA in EPN at diagnosis predicts an increased risk of recurrence in childhood ependymoma. IL-13RA2 is a potentially attractive target for innovative therapy in children with ependymoma at an increased risk of recurrence. No significant financial relationships to disclose.
Use of thrombin-receptor 1 (PAR-1), endostatin (ES), and interleukin-8 (IL-8) gene polymorphisms to predict tumor recurrence in patients with surgically resected gastric cancer
Authors: G. Lurje, H. Husain, A. E. Hendifar, W. Zhang, D. Yang, A. Pohl, P. C. Manegold, Y. Ning, S. Iqbal, A. B. El- Khoueiry, H. J. Lenz
Journal: Journal of Clinical Oncology (2008)

4559 Background: Tumor recurrence continues to be a significant problem in the management of patients with surgically resected gastric cancer. Thrombin-receptor 1 (PAR1) has been described to counter-regulate the release of endostatin (ES) and VEGF from human platelets. PAR-1 could therefore play a crucial role in the regulation of tumor angiogenesis and in turn may regulate the process of tumor invasion and metastasis. Further, interleukin-8 (IL-8) has been reported to play a major role in VEGF-independent tumor angiogenesis. We tested whether 14 functionally significant gene polymorphisms within 8 genes involved in the tumor angiogenesis pathway, will predict tumor recurrence in patients with surgically resected gastric cancer. Methods: Between 1992 and 2007 blood specimens from 105 patients (41 females and 64 males; median age=57 yrs; range=26–85 yrs) were obtained at the University of Southern California medical facilities. The median follow-up was 2.4 years (range=0.1–12.3). 47 of 105 patients (45%) developed tumor recurrence with a 5-year probability of 0.38 ± 0.06. Genomic DNA was isolated from peripheral blood and genotypes were determined using PCR-RFLP. Results: High-expression variants of PAR-1 -506 (median TTR: 1.2 yrs) and IL-8 -251 (median TTR: 1.6 yrs) as well as low-expression variants of ES +4349 (median TTR: 2.2 yrs) were associated with an increased likelihood of tumor recurrence, compared to other genotype combinations of PAR-1 (median TTR: 2.3 yrs), IL-8 (median TTR: 2.9 yrs), and ES (median TTR: 2.9 yrs). In multivariate analysis, polymorphisms in PAR-1 (adjusted p=0.04) and IL-8 (adjusted p=0.03) showed to be independent prognostic factors for TTR. Conclusions: PAR-1 I- 506D, ES G+4349A, and IL-8 T-251A polymorphisms may help to identify gastric cancer patients who are at increased risk to develop tumor recurrence. Thus targeting PAR-1, ES and IL-8 may be of clinical benefit in patients with surgically resected gastric cancer. Larger, prospective and biomarker embedded clinical trials are needed to validate these preliminary data. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Expert Testimony Other Remuneration Bristol-Myers Squibb, Genentech™ BioOncology, ImClone Systems Incorporated, Merck, Pfizer Oncology, Response Genetics Genentech™ BioOncology, Merck, Pfizer Oncology, Roche, sanofi-aventis
Predictive value of heparanase expression in the palliative therapy of pancreatic cancer
Authors: K. Caca, J. Kronberg, A. Tannapfel, C. Wittekind, J. Moessner, K. Schoppmeyer
Journal: Journal of Clinical Oncology (2005)

9577 Background: Patients with pancreatic ductal adenocarcinoma (PDA) have a median survival of less than six months from diagnosis. Palliative chemotherapy with the current standard gemcitabine does only marginally improve median survival. There may be subgroups of patients receiving palliative therapy that have a better prognosis. Heparanase, an endoglycosidase degrading components of the extracellular matrix, promotes cell invasion, is involved in angiogenesis and plays a role in tumour metastases. It is expressed in PDA and its expression is associated with shorter postoperative survival after pancreatic resections. Methods: In the present study we examined heparanase expression as a prognostic marker in patients receiving palliative chemotherapy with gemcitabine for inoperable PDA. Tissue sections were stained by immunohistochemistry and qualitatively analysed for heparanase expression. Progression free survival according to imaging procedures and overall survival was recorded. Results: Heparanase expression was detectable by immunohistochemistry in 36 out of 58 (62%) patients analysed. Overall survival was 7.4 months versus 13.3 months (p=0.006) in heparanase positive and negative tumours, respectively. Progression free survival was 1.3 versus 3.4 months, respectively (p=0.47). Conclusions: Heparanase expression may be a useful marker to predict response to palliative therapy with gemcitabine in PDA. No significant financial relationships to disclose.
Infusion-Related Phlebitis
Authors: S Danchaivijitr, N Srihapol, S Pakaworawuth, S Vaithayapiches, T Judang, V Pumsuwan, K Kachintorn
Journal: New England Journal of Medicine (1985)

The incidence rate and risk factors of infusion-related phlebitis was studied in 1993. Thirty-five hospitals were enrolled. Data were collected from 6,256 infusion sites. Male and female patients were almost equal. Forearms were the commonest site of infusion, followed by hand and arm respectively. In 34.1 per cent the infusion was interrupted by complications of which 6.2 per cent was phlebitis. It was mild in most cases. Increased incidence rates of infusion related phlebitis were associated with: the use of plastic cannulas, dextrose containing solutions, administration at the sites other than hand and concomitant administration of antimicrobials. The incidence rate of phlebitis rose sharply after 24 hours of infusion. It is concluded that in addition to proper insertion and good nursing care, the avoidance of the above risk factors will lead to a lower incidence of infusion-associated phlebitis.
High Th17:Treg ratio may predict complete response to HDIL-2 in the setting of melanoma
Authors: Maggie L Diller, Ford Mandy, Keith A Delman, David H Lawson
Journal: Journal for ImmunoTherapy of Cancer (2015)

Meeting abstracts In vitro and in vivo experiments have demonstrated a potent yet opposite effect of IL-2 on both regulatory T cells (TREG) and IL-17+CD45RA-CD4+ T cells (Th17). TREG cells have been implicated as an important immunoregulator enhancing tumor growth whereas Th17 cells may mediate
The mechanisms of apoptosis induced by artistical composition of Chinese medicinal herbs in gastric cancer metastasis
Authors: J. Li, G. Sun
Journal: Journal of Clinical Oncology (2006)

14147 Background: In China, gastric cancer has been treated by Chinese medicinal herbs to prevent relapse and metastasis for decades. The purpose of this study is to investigate the effectiveness and the mechanism of artistical composition of Chinese medicinal herbs (YWKL) in preventing gastric cancer metastasis. Methods: The herbs, after decoction, were administered by feeding 615 mice, which is a proventriculus cancer (FC) transplanted model, the rate of its lung metastasis rate is 70–80%. The inhibitory effect of artistical composition of Chinese medicinal herbs on FC spontaneous lung metastasis was evaluated by histological classification method. Apoptosis were determined through TUNEL technique. The expression of apoptosis relative gene was determined by immunohistochemical methods. Results: It has been found that YWKL can significantly decrease the tumorous node numbers in the lung, while increase the apoptosis cell index (AI) of tumor cell metastasizing to lung. We found the expression of Fas,Bax were much higher than that of control group, FasL and Bcl2 were no significantly different between the two groups. Conclusions: The oral application of the herbs after decoction was demonstrated to prevent gastric cancer metastasis mice model. The mechanism of YWKL-induced apoptosis in FC cancer cell might through regulating the expression of Fas and Bax genes. No significant financial relationships to disclose.
Long-term safety of infliximab (INX) with methotrexate (MTX) in a large belgian observational patient cohort with severe, refractory rheumatoid arthritis (RA)
Authors: Patrick Durez, Jean-Pierre Devogelaer, B. Vander Cruyssen, F. Vandenbosch, N. Vastesaeger, A. Geldhof, F. De Keyser, L. Verbruggen, L. De Clerck, A. Peretz, Michel Malaise, F. Van Heuverbeke, Rene Westhovens
Journal: Annals of the Rheumatic Diseases (2006)